Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2021-06-09 17:00:13
Lille/Oslo, 9 June 2021
Reference is made to the stock exchange announcement earlier today, 9 June 2021,
regarding Compagnie des Levures Lesaffre's ("Lesaffre") announcement of a
compulsory acquisition of all shares in NattoPharma ASA ("NattoPharma" or the
"Company") not already owned by Lesaffre.
The Board of Directors of Lesaffre has, effective from close of trading on Oslo
Børs today, 9 June 2021, resolved to carry out the compulsory acquisition of all
remaining shares in NattoPharma not owned by Lesaffre, pursuant to the Norwegian
Public Limited Liability Companies Act section 4-25 cf. the Norwegian Securities
Trading Act section 6-22 (1). As a consequence, Lesaffre has assumed ownership
of all shares in the Company.
The offered redemption price under the compulsory acquisition is NOK 35.00 per
share, which corresponds to the offer price in the preceding mandatory offer
and, according to the Norwegian Securities Trading Act section 6-22 (2), is the
applicable redemption price in a subsequent compulsory acquisition. Lesaffre has
deposited the total acquisition amount on a separate account with Nordea, in
accordance with the Norwegian Public Limited Liability Companies Act section 4
-25 (5).
A notice regarding the compulsory acquisition will be sent to all former
shareholders subject to the compulsory transfer, whose addresses are known. In
addition, the compulsory acquisition will be announced through the electronic
notice service of the Norwegian Register of Business Enterprises (Nw.
Brønnøysundregistrene) if required pursuant to applicable law.
As a consequence of the compulsory acquisition, Lesaffre will pursue a de
-listing of the Company's shares from Euronext Expand. Separate stock exchange
notices will be published regarding the timing for such delisting.
Oslo Børs is requested to suspend the Company's shares from trading without
delay.
Rothschild is acting as financial adviser to Lesaffre and Nordea Bank Abp,
filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is
acting as the Norwegian legal adviser, and Linklaters is acting as the French
legal adviser, to Lesaffre.
For further information, please contact:
NattoPharma:
NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com
Lesaffre:
Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr